Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACDN-01 in ABCA4-related Retinopathy
NCT06467344Phase 2Recruiting
- Sponsor
- Ascidian Therapeutics
- Start
- Jun 2024
- Primary completion
- Aug 2030
- Modality
- Gene Editing, Gene Silencing, RNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of ACDN-01 in ABCA4-related retinopathy (ABCA4R), Stargardt disease (STGD) and cone-rod dystrophy (CRD) (3 arms), sponsored by Ascidian Therapeutics. Primary endpoint: Number and severity of adverse events and serious adverse events at 12 months. Started Jun 2024; status: recruiting.
02
Drugs
ACDN-01
03
Conditions
ABCA4-related retinopathy (ABCA4R)Stargardt disease (STGD)cone-rod dystrophy (CRD)
Beyond the preview
Go deeper on NCT06467344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06467344.